| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
CRSP
Crispr Therapeutics AG
|
Aug 25, 2025 | BUY |
Buy
+39.7% avg upside
41 analysts
|
$99.00
83.02% Upside
|
-3.9% |
|
SVRA
Savara
|
Aug 04, 2025 | HOLD |
Strong Buy
+58.2% avg upside
17 analysts
|
$2.00
63.57% Downside
|
+95.7% |
|
ANTX
AN2 Therapeutics, Inc.
|
Jul 31, 2025 | SELL |
Buy
+75.0% avg upside
7 analysts
|
$2.00
59.98% Downside
|
-348.1% |
|
RARE
Ultragenyx Pharmaceutical
|
Jul 10, 2025 | BUY |
Strong Buy
+142.0% avg upside
36 analysts
|
$70.00
155.18% Upside
|
-25.5% |
|
ALT
Altimmune
|
Jun 27, 2025 | BUY |
Strong Buy
+935.8% avg upside
19 analysts
|
$25.00
825.91% Upside
|
-17.1% |
|
TVTX
Travere Therapeutics
|
Jun 16, 2025 | BUY |
Strong Buy
-15.9% avg upside
22 analysts
|
$45.00
18.38% Downside
|
+254.5% |
|
INSM
Insmed
|
Jun 11, 2025 | BUY |
Strong Buy
+82.1% avg upside
36 analysts
|
$110.00
14.88% Upside
|
-1.3% |
|
VERA
Vera Therapeutics
|
Jun 06, 2025 | BUY |
Strong Buy
+91.0% avg upside
19 analysts
|
$75.00
113.79% Upside
|
+42.2% |
|
NTLA
Intellia Therapeutics
|
May 29, 2025 | BUY |
Buy
+153.7% avg upside
37 analysts
|
$48.00
206.22% Upside
|
+88.9% |
|
VRTX
Vertex Pharmaceuticals
|
May 20, 2025 | BUY |
Strong Buy
-2.7% avg upside
61 analysts
|
$510.00
12.85% Upside
|
-3.7% |
|
EDIT
Editas Medicine
|
May 13, 2025 | BUY |
Buy
+420.3% avg upside
33 analysts
|
$4.00
48.64% Upside
|
+93.3% |
|
ENTA
Enanta Pharmaceuticals
|
May 13, 2025 | BUY |
Buy
+159.2% avg upside
17 analysts
|
$20.00
58.06% Upside
|
+168.3% |
|
CRBU
Caribou Biosciences
|
May 12, 2025 | HOLD |
Strong Buy
+581.8% avg upside
12 analysts
|
$1.00
39.07% Downside
|
+147.6% |
|
KNSA
Kiniksa Pharmaceuticals
|
May 12, 2025 | BUY |
Strong Buy
-0.2% avg upside
11 analysts
|
$35.00
36.46% Downside
|
+121.6% |
|
BCRX
BioCryst
|
May 06, 2025 | BUY |
Strong Buy
+103.2% avg upside
24 analysts
|
$12.00
33.42% Upside
|
-14.0% |
|
ALNY
Alnylam Pharma
|
May 06, 2025 | BUY |
Strong Buy
+23.4% avg upside
51 analysts
|
$280.00
0.70% Upside
|
+12.3% |
|
MDGL
Madrigal Pharmaceuticals
|
May 02, 2025 | BUY |
Strong Buy
-5.8% avg upside
31 analysts
|
$392.00
22.57% Downside
|
+62.8% |
|
AURA
Aura Biosciences Inc
|
Mar 31, 2025 | BUY |
Strong Buy
+234.5% avg upside
9 analysts
|
$20.00
215.44% Upside
|
+14.2% |
|
CARM
Carisma Therapeutics
|
Dec 11, 2024 | HOLD |
Buy
+15294.7% avg upside
11 analysts
|
$0.70
3584.19% Upside
|
-90.8% |
|
IPHA
Innate Pharma
|
Nov 14, 2024 | BUY |
Strong Buy
+264.7% avg upside
10 analysts
|
$5.00
176.28% Upside
|
+9.3% |
|
TBPH
Theravance Biopharma
|
Nov 13, 2024 | HOLD |
Buy
+12.2% avg upside
18 analysts
|
$11.00
33.65% Downside
|
+85.4% |
|
JBIO
Jade Biosciences
|
Jun 17, 2024 | HOLD |
Strong Buy
+232.8% avg upside
16 analysts
|
$70.00
316.14% Upside
|
-85.3% |
|
VST
Vistra Corp
|
Oct 17, 2023 | BUY |
Strong Buy
+23.1% avg upside
22 analysts
|
$35.00
78.72% Downside
|
+296.4% |
|
ABUS
Arbutus Biopharma
|
Jul 27, 2020 | BUY |
Strong Buy
+94.1% avg upside
15 analysts
|
$8.00
75.77% Upside
|
-39.6% |
|
SRPT
Sarepta Therapeutics
|
Apr 28, 2020 | BUY |
Buy
+246.5% avg upside
49 analysts
|
$217.00
1137.82% Upside
|
-41.5% |
|
DBVT
DBV Technologies SA - American
|
Mar 17, 2020 | BUY |
Strong Buy
+55.4% avg upside
15 analysts
|
$10.00
35.64% Downside
|
+139.1% |
|
HRTX
Heron Therapeutics
|
Jan 13, 2020 | BUY |
Strong Buy
+6439.5% avg upside
21 analysts
|
$32.00
7564.77% Upside
|
-18.2% |
|
PRQR
ProQR
|
Nov 06, 2019 | BUY |
Strong Buy
+516.3% avg upside
18 analysts
|
$25.00
1222.77% Upside
|
-45.8% |
|
INCY
Incyte
|
Feb 07, 2019 | HOLD |
Buy
+1.0% avg upside
47 analysts
|
— | -7.1% |
|
CRBP
Corbus Pharmaceuticals
|
Sep 20, 2018 | BUY |
Strong Buy
+338.6% avg upside
20 analysts
|
$27.00
226.78% Upside
|
-33.8% |
|
SMMT
Summit Therapeutics
|
Sep 20, 2018 | HOLD |
Strong Buy
+112.6% avg upside
27 analysts
|
— | -36.6% |
|
CYTOF
Altamira Therapeutics
|
Nov 11, 2016 | HOLD |
Strong Buy
+16248.7% avg upside
4 analysts
|
— | · |
|
SCYX
SCYNEXIS
|
Jun 09, 2016 | BUY |
Strong Buy
+225.1% avg upside
10 analysts
|
$10.00
146.84% Upside
|
-45.8% |
|
ANTH
Anthera Pharmaceuticals
|
Jun 28, 2012 | HOLD |
Buy
+472857042.9% avg upside
9 analysts
|
— | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.